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Abstract
The study of clinical samples is often limited by the amount of material available to study. While
proteins cannot be multiplied in their natural form, DNA and RNA can be amplified from small
specimens and used for high-throughput analyses. Therefore, genetic studies offer the best
opportunity to screen for novel insights of human pathology when little material is available. Precise
estimates of DNA copy numbers in a given specimen are necessary. However, most studies
investigate static variables such as the genetic background of patients or mutations within
pathological specimens without a need to assess proportionality of expression among different
genes throughout the genome. Comparative genomic hybridization of DNA samples represents a
crude exception to this rule since genomic amplification or deletion is compared among different
specimens directly. For gene expression analysis, however, it is critical to accurately estimate the
proportional expression of distinct RNA transcripts since such proportions directly govern cell
function by modulating protein expression. Furthermore, comparative estimates of relative RNA
expression at different time points portray the response of cells to environmental stimuli, indirectly
informing about broader biological events affecting a particular tissue in physiological or
pathological conditions. This cognitive reaction of cells is similar to the detection of
electroencephalographic patterns which inform about the status of the brain in response to
external stimuli. As our need to understand human pathophysiology at the global level increases,
the development and refinement of technologies for high fidelity messenger RNA amplification have
become the focus of increasing interest during the past decade. The need to increase the
abundance of RNA has been met not only for gene specific amplification, but, most importantly for
global transcriptome wide, unbiased amplification. Now gene-specific, unbiased transcriptome wide
amplification accurately maintains proportionality among all RNA species within a given specimen.
This allows the utilization of clinical material obtained with minimally invasive methods such as fine
needle aspirates (FNA) or cytological washings for high throughput functional genomics studies.
This review provides a comprehensive and updated discussion of the literature in the subject and
critically discusses the main approaches, the pitfalls and provides practical suggestions for successful
unbiased amplification of the whole transcriptome in clinical samples.
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Quantification of gene expression is a powerful tool for
the global understanding of the biology underlying com-
plex pathophysiological conditions. Advances in gene
profiling analysis using cDNA or oligo-based microarray
systems uncovered genes critically important in disease
development, progression, and response to treatment [1-
12]. While the expression of a single or a limited number
of genes can be readily estimated using minimum amount
of total or messenger RNA (mRNA) from experimental or
clinic samples, gene profiling requires large amount of
RNA which can only be generated from global RNA
amplification when using often limited amount clinical
material. Conventionally at least 50 – 100 µg of total RNA
(T-RNA) or 2 – 5 µg poly(A)+ RNA are generally necessary
for global transcript analysis studies though efforts to
enhance signal intensity and fluorochrome incorporation
have reduced the amount of total RNA needed for array
analysis to 1–5 ug [13]. Large amounts of RNA are not
usually obtainable from clinical specimens. Thus, they
pertain to experimental endeavors where cultured cell
lines or tissues from pooled experimental models are used
while only occasionally they are obtainable from large
excisional biopsies [14]. However, most biological speci-
mens directly obtained ex vivo for diagnostic or prognostic
purposes or for clinical monitoring of treatment are too
scarce to yield enough RNA for high throughput gene
expression analysis. Needle or punch biopsies provide the
opportunity to serially sample lesions during treatment or
to sample lesion to identify predictors of treatment out-
come by observing the fate of the lesion left in place. In
addition, the simplicity of the storage procedure associ-
ated with the collection of small samples which can be
performed at the bed side provides superior quality of
RNA with minimum degradation [15]. Finally, the
hypoxia which follows ligation of tumor-feeding vessels
before excision is avoided with these minimally invasive
methods, therefore, obtaining a true snapshot of the in
vivo transcriptional program. These minimally invasive
sampling techniques yield generally few micrograms of
total RNA and most often even less [15,16]. Similarly,
breast and nasal lavages and cervical brush biopsies, rou-
tinely used for pathological diagnosis, generate insuffi-
cient material far below the detection limit of most assays.
Acquisition of cell subsets by fluorescent or magnetic sort-
ing or laser capture micro-dissection (LCM) for a more
accurate portraying of individual cell interactions in a
pathological process generate even less material, in most
cases, nanograms of total RNA [17-20].
Efforts have been made to broaden the utilization of
cDNA microarrays using two main strategies: intensifying
fluorescence signal [13,21-24] or amplifying RNA. Signal
intensification approaches have reduced the requirement
of RNA few folds but cannot extend the utilization of
microarray to sub-microgram levels. RNA amplification in
turn has gained extreme popularity based on amplifica-
tion efficiency, linearity and reproducibility lowering the
amount of total RNA needed for microarray analysis to
nanograms without introducing significant biases. Meth-
ods aimed at the amplification of poly(A)-RNA [25] via in
vitro transcription (IVT) [26] or cDNA amplification via
polymerase chain reaction (PCR) [27] have reduced the
material needed for cDNA microarray application and
extended the spectrum of clinical samples that can be
studied. Nanograms of total RNA have been successfully
amplified into micrograms of pure mRNA for the screen-
ing of the entire transcriptome without losing the propor-
tionality of gene expression displayed by the source
material. Curiously, the most important advances were
made by Eberwine whose main goal was not to use clini-
cal material for high-throughput studies but rather to
amplify enough material from single cells for individual
or few gene analysis [28,29]. His revolutionary contribu-
tion has, however, provided a striking opportunity to
explore the function of the human genome ex vivo and has
exponentially opened the frontiers of clinical investiga-
tion. Modifications, optimizations and validations of
RNA amplification technology based on Eberwine's pio-
neering work are still actively explored.
In this chapter, we will summarize efforts to optimize
RNA amplification and describe in detail current amplifi-
cation procedures that have been validated and applied to
cDNA microarray analysis.
Collection of source material and RNA isolation
Samples used for RNA isolation and amplification should
always be collected fresh and immediately processed.
Excisional biopsies should be handled within 20 min and
stored at -80°C (for instance with RNAlater™, Ambion,
Austin, TX) if RNA isolation cannot be performed right
away. Material from FNA should be collected in 5 ml of
ice cold 1 × PBS or other collection medium without
serum at the patient's bedside to minimize RNA metabo-
lism or degradation. After spinning at 1,500 rpm for 5
minutes at 4°C, 2.5 ml of ACK lysing buffer should be
added with 2.5 ml of 1 × PBS and incubated for 5 minutes
on ice to lyse red blood cells (RBC) in case of excessive
contamination. Cell pellets should be washed in 10 ml 1
× PBS and then re-suspend in small volumes of RNAlater
followed by snap freezing or prior lysis of the pellet in 350
µl of RLT buffer with fresh addition of 2-mercaptoethanol
(2-ME) (RNeasy mini kit, QIAGEN Inc, Valencia, CA USA)
before snap freezing at -80°C. For LCM, good results can
be obtained by lysing cells directly in 50 µl RLT buffer
with 2-ME. Total RNA (T-RNA) and poly A RNA can both
be used as starting material for RNA amplification.Page 2 of 11
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quantity of RNA. T-RNA can be isolated using commer-
cially available RNA isolation kits. The T-RNA content per
mammalian cell ranges between 20 to 40 pg of which only
0.5 – 1.0 pg are constituted by messenger RNA (mRNA)
[30,31]. Sample condition, viability, functional status and
phenotype of the cells are the major reasons for differen-
tial yield of T-RNA. Sample handling with precaution for
RNase contamination always improves the quality and
quantity of the RNA obtained. Measurement of T-RNA
concentration can be performed with a spectrophotome-
ter at OD260. An OD260/280 ratio above 1.8 is to be
expected. When a very limited number of cells is available
such as from LCM or FNA, very low or even negative OD
readings may be observed. In this case, OD reading can be
omitted. When RNA is isolated from archived samples or
from samples whose collection and storage conditions
were not controlled and optimized, it is preferable to esti-
mate RNA quality and quantity using Agilent Bioanalyzer
(Agilent Technologies Inc. Palo Alto, CA) or RNA gels.
Clear 28S and 18S ribosomal RNA bands indicate good
quality of RNA. Since 28S rRNA degradation occurs earlier
than 18S rRNA and mRNA degradation in most cases cor-
relates with 28S ribosomal RNA, the ratio of 28S versus
18S rRNA is a good indicator of mRNA quality [32]. 28S/
18S rRNA ratios equal or close to 2 suggest good RNA
quality.
Single strand cDNA synthesis
A critical step in RNA or cDNA amplification is the gener-
ation of double stranded cDNA (ds-cDNA) templates.
First strand cDNAs are reverse transcribed from mRNA
using oligo dT or random primers. In order to generate
full length first strand cDNA, oligo dT(15–24 nt) with an
attachment of a bacterial phage T7 promoter sequence is
commonly used to initiate the cDNA synthesis [25,29,33-
36]. In case of degraded RNA [37], random primers with
attachment of T3 RNA polymerase promoter (T3N9) have
been used for first and second strand cDNA synthesis [38].
To prevent RNA degradation while denaturing and during
the reverse transcription (RT) reaction, it is useful to dena-
ture the RNA (65°C for 5 minutes or 70°C for 3 minutes)
in the presence of RNasin® Plus RNase Inhibitor
(Promega, Madison, WI) which forms a stable complex
with RNases and inactivates RNase at temperatures up to
70°C for at least 15 minutes.
To enhance the efficiency of the RT reaction and reduce
incorporation errors, the temperature of the RT reaction
can be maintained at 50°C [39,40] instead of 42°C to
avoid the formation of secondary mRNA structures. This
can be done by using thermo-stable reverse transcriptase
(ThermoScript™ RNase H- Reverse Transcriptase, Invitro-
gen, Carlsbad, CA) or regular RTase [41] in the presence of
disaccharide trehalose [42-44]. Disaccharide trehalose not
only can enhance the thermo-stability of RTase but also
posses thermo-activation functions. This modification
greatly enhances the accuracy and the efficiency of RT with
minimum impact on the DNA polymerase activity [39].
The utilization of DNA binding protein T4gp32 (USB,
Cleveland) in RT reactions also improves cDNA synthesis
[40,41,45,46]. T4gp32 protein may essentially contribute
to the qualitative and quantitative efficiency of the RT
reaction by reducing higher order structures of RNA mol-
ecules and hence reduce the pause sites during cDNA syn-
thesis.
In Van Gelder and Eberwine's T7 based RNA amplifica-
tion [28], the amount of oligo dT-T7 primer used in the
first strand cDNA synthesis can affect the amplified RNA
in quantity and quality. Excessive oligo dT-T7 in the RT
reaction could lead to template independent amplifica-
tion [47]. This phenomenon is not observed when the
template switch approach is combined to in vitro tran-
scription (Wang, E. unpublished data).
Double stranded cDNA (ds-cDNA) synthesis
RNA amplification methods differ according to the strate-
gies used for the generation of ds-cDNA as templates for
in vitro transcription or PCR amplification. There are two
basic strategies that have been extensively validated and
applied for high throughput transcriptional analysis. The
first is based on Gubler-Hoffman's [48] ds-cDNA synthe-
sis subsequently optimized by Van Gelder and Eberwine
[28,29]. This technology utilizes RNase H digestion to cre-
ate short fragments of RNA as primers to initiate the sec-
ond strand cDNA elongation under DNA polymerase I.
Fragments of second strand cDNA are then ligated to each
other sequentially under E. Coli DNA ligase followed by
polishment using T4 DNA polymerase to eliminate loops
and to form blunt ends. Amplifications based on this
methods have been widely used in samples obtained in
physiological or pathological conditions and extensively
validated for its fidelity, reproducibility and linearity com-
pared to un-amplified RNA from the same source materi-
als [29,33,47,49-52].
The alternative ds-cDNA synthesis approach utilizes retro-
viral RNA recombination as a mechanism for template
switch to generate full length ds-cDNA. The method was
initially invented for full length cDNA cloning and, there-
fore, the main targets of this method are undegredated
transcripts. Gubler-Hoffman's ds-cDNA synthesis has the
potential of introducing amplification biases because of a
possible 5' under-representation. In addition, the low
stringency of the temperature in which ds-cDNA synthesis
occurs may introduce additional biases [33]. Although 5'
under-representation could, in theory, be overcome by
hairpin loop second-strand synthesis [53], the multiplePage 3 of 11
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errors.
To ensure generation of full-length ds-cDNA, [54] synthe-
sis is performed taking advantage of the intrinsic terminal
transferase activity and template switch ability of Moloney
Murine Leukemia Virus RTase [55]. This enzyme adds
non-template nucleotides at the 3' end of the first strand
cDNA, preferentially dCTP oligo nucleotides. A template-
switch oligonucleotide (TS primer) containing a short
string of dG residues at the 3' end is added to the reaction
to anneal to the dC string of the newly synthesized cDNA.
This produces an overhang that allows the RTase to switch
template and extend the cDNA beyond the dC to create a
short segment of ds-cDNA duplex. After treatment with
RNase H to remove the original mRNA, the TS primer ini-
tiates the second stranded cDNA synthesis by PCR. Since
the terminal transferase activity of the RTase is triggered
only when the cDNA synthesis is complete, only full-
length single stranded cDNA will be tailed with the TS
primer and converted into ds-cDNA. Using the TS primer,
second strand cDNA synthesis is carried at 75°C after a
95°C denaturing and a 65°C annealing step in the pres-
ence of single DNA polymerase [35]. This technique, in
theory, overcomes the bias generated by amplification
methods depending only on 3' nucleotide synthesis and
hence it is, in theory, superior to the Gubler-Hoffman's
ds-cDNA synthesis. However, no significant differences in
correlation coefficients of amplified versus non amplified
RNA were observed when the Gubler-Hoffman's ds-cDNA
method was compared with the TS ds-cDNA amplifica-
tion using high throughput analysis [40,56] The fidelity of
template switch-based amplification methods has been
assessed by numerous gene profiling analyses on different
type of microarray platforms, real time PCR and sophisti-
cated statistical analyses and it has been well accepted for
high throughput transcriptome studies.
RNA amplifications
Linear amplification
Amplification of mRNA without skewing relative tran-
script abundance remains a focus of research. Linear
amplification methods have been developed that in the-
ory should maintain the proportionality of each RNA spe-
cies present in the original sample. IVT using ds-cDNA
equipped with a bacteriophage T7 promoter [28] provides
an efficient way to amplify mRNA sequences and thereby
generate templates for synthesis of fluorescently-labeled
single-stranded cDNA [25,26,28,29,33,53]. Depending
upon the T7 or other (T3 or SP6) promoter sequence posi-
tion on the ds-cDNA, amplified RNA can be either in
sense or antisense orientation. Oligo dT attachments to
the promoter sequence, for example oligo dT-T7, prime
first strand cDNA positioned the promoter at the 3' end of
genes (5' end of cDNA) and, therefore, lead to the ampli-
fication of antisense RNA (aRNA) or complement RNA
(cRNA). Promoters positioned at the 5' end of genes by
random [57] or TS primers (Wang E, unpublished obser-
vation) generate sense RNA (sRNA). Amplified sRNA can
be also produced by tailing of oligo dT to the 3' of the
cDNA followed by oligo dA-T7 priming for double
stranded T7 promoter generation at the 5' end of genes
[58]. The singularity of this approach resides in the utili-
zation of a DNA polymerase blocker at the 3' of the oligo
dA-T7 primer which prevents the elongation of second
strand cDNA synthesis while priming for the elongation
of the double stranded promoter. In this fashion, only
sense amplification can be achieved by the presence of the
5' ds-T7 promoter followed by single strand cDNA tem-
plates.
IVT using DNA-dependent RNA polymerase is an isother-
mal reaction with linear kinetics. The input ds-cDNA tem-
plates are the only source of template for the complete
amplification and, therefore, any errors created on the
newly synthesized RNA will not be carried or amplified in
the following reactions. Overall, RNA polymerase makes
an error at a frequency of about once in 10,000 nucle-
otides corresponding to about once per RNA strand cre-
ated http://www.rcsb.org/pdb/molecules/pdb40_1.html.
This contrasts with DNA-dependent DNA polymerase
which incorporates an error once in every 400 nucle-
otides. Most importantly, these errors are exponentially
amplified in the following reaction since the amplicons
serve as templates. Thus, RNA polymerase catalyzes tran-
scription robotically and efficiently without sequence
dependent bias. Recombinant RNA polymerases have
been engineered to enhance the stability of the enzyme
interacting with templates and reduce the abortive ten-
dency [59] of the wild type RNA polymerase which in turn
improved the elongation phase resulting in complete
mRNA transcripts. The length of amplified RNA ranges
from 200 to 6,000 nucleotides for the first round of
amplification and 100 to 3,000 nucleotides for the second
round when random primers are used [36,60] The ampli-
fication efficiency is greater than 2,000 fold in the first
round and 100,000 fold in the second round [35,60]
Two rounds of IVT are commonly required when sub
micrograms of input total RNA are used. It has been esti-
mated that after two rounds of amplification the fre-
quency of only 10% of the genes in a specimen is reduced
[61] and more than two rounds of amplification may still
retain at least in part the proportionality of gene expres-
sion among different RNA populations [35]. However,
we, generally, do not recommend going over two rounds
of amplification unless necessary for extremely scant spec-
imens such as when processing single or few cell speci-
mens, to avoid unnecessary biases related to
amplification. The fidelity of IVT has been extensivelyPage 4 of 11
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PCR and statistical testing by comparing estimates of gene
expression in amplified versus non-amplified RNA [35].
Pitfalls have been also associated with IVT. The fidelity of
the first round amplification decreases when the input
starting material is less than 100 ng because of the intrin-
sic low abundance of transcripts (particularly those under
represented in the biological specimen). This can be res-
cued by two rounds of IVT if sufficient RNA species are
present in the input material [35]. In addition, two rounds
of amplification tend to introduce a 3' bias due to the use
of random primers in the cDNA synthesis for ds-cDNA
template creation. This should not affect the usefulness of
the technique for high throughput gene profiling analysis
since cloned cDNA arrays are 3' biased and even oligo
arrays are designed to target the 3' end of each gene.
Sequence-specific biases introduced during amplification
are generally reproducible and, although negligible, could
mislead data interpretation only when amplified RNA is
directly compared with non amplified RNA on the same
array platform. This type of error can be easily circum-
vented by using samples processed in identical condi-
tions. Degradation of amplified RNA during prolonged
(more than 5 hours) IVT may result in lower average size
of aRNA and decreased yields [37]. This results from resid-
ual RNase in the enzyme mixture used for IVT reaction
and can be prevented by the addition of RNase inhibitor
in the reaction if a prolonged amplification is needed.
PCR-based exponential amplification
IVT is burdensome time consuming and may, theoreti-
cally, produce a 3' bias especially when two rounds of
amplification are employed. Exponential amplification
(PCR-based) may avoid these drawback and it has shown
promise since, contrary to the IVT, is simple and efficient.
However, PCR-based amplification has its own draw-
backs.
The limitations of PCR-based amplification stem from the
characteristics of the DNA-dependent DNA polymerase
enzymatic function. The function of this enzyme is biased
towards a lower efficiency in the amplification of GC rich
sequences compared with AT rich sequences. In addition,
as previously discussed, not only creates errors more fre-
quently than RNA polymerase but also amplifies these
mistakes because the reaction utilizes the amplicons as
templates for subsequent amplification [62]. In addition,
due to the exponential amplification, the reaction could
reach saturation in conditions in which excess input tem-
plate quantities are used or because of the exhaustion of
substrate. This would favor the amplification of high-
abundance transcripts which would compete more effi-
ciently for substrate in the earlier cycles of the amplifica-
tion process resulting in loss of proportionality of the
amplification process. Optimization of PCR cycle number
to avoid reaching the saturation cycle and adjustments in
the amount of template input could overcome the prob-
lems [63]. The utilization of DNA polymerase with proof-
reading function could eradicate errors created in the
cDNA amplification [64]. This approach preserves the rel-
ative abundance of transcript [65] and it may outperform
IVT when less than 50 ng of input RNA are available as
starting material [66,67].
PCR-based cDNA amplification can be categorized as tem-
plate switching (TS)-PCR [52,68,69], random PCR [70]
and 3' tailing with 5' adaptor ligation PCR [71] based on
the generation of a 5' anchor sequence which provides a
platform for 5' primer annealing. TS-PCR employs the
same template switch mechanism in ds-cDNA generation
and in the amplification of ds-cDNA using 5' TS primer II
(truncated TS primer) and 3' oligo dT or dT-T7 primers
(depending upon the primer used in the first strand cDNA
synthesis). Random PCR utilizes modified oligo dT prim-
ers (dT-T7 or dT-TAS (Target Amplification Sequence) or
random primers with an adaptor sequence for the first
strand cDNA initiation and random primers with an
attachment of the same adaptor, for example dN10-TAS
[70], for second strand cDNA synthesis. The attached
sequence, such as TAS, generates a 5' anchor on the cDNA
for subsequent PCR amplification with a single TAS-PCR
primer. This approach is more suitable for RNA with par-
tial degradation and with the risk of under representation
of the 5' end. The third exponential amplification utilizes
terminal deoxynucleotidyl transferase function to add a
polymonomer, for example poly dA, tail to the 5' end of
the gene. The tailed poly dA provides an annealing posi-
tion for the oligo dT primer which lead the second strand
cDNA synthesis. Ds-cDNA can then be amplified under
one oligo dT primer or dT-adaptor primer if an adaptor
sequence is attached [66]. Direct adaptor ligation is
another alternative way to generate ds-cDNA with a
known anchor sequence at the 5' end [71]. In this way,
single strand cDNA is generated using oligo dT primers
immobilized onto magnetic beads and second strand
cDNA is completed by Van Gelder and Eberwine's ds-
cDNA generation method. A ds-T7 promoter-linker is
then unidirectionally ligated to the blunted ds-cDNA at
the 5' end. PCR amplification can then be performed
using the 5' promoter primer and the 3' oligo dT or dT-
adapter primer, if an adapter is attached. PCR amplified
ds-cDNA is suitable for either sense or antisense probe
arrays.
The combination of PCR amplification to generate suffi-
cient ds-cDNA template followed by IVT [70,71]. is an
attractive strategy to amplify minimal starting material
since it takes advantage of the efficiency of the PCR reac-
tion and the linear kinetics of IVT while minimizing thePage 5 of 11
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RNA amplification methods are fewer than those for IVT
but have been so far persuasive in spite of the prevalent
expectations. Skepticism concerning the reproducibility
and linearity are still one of the key factors preventing the
extensive application of this approach.
Target labeling for cDNA microarray using amplified RNA
The generation of high quality cDNA microarray data
depends not only on sufficient amount and highly repre-
sentative amplified target, but also on the target labeling
efficacy and reproducibility. Steps involved in the targets
preparation such as RNA amplification, target labeling,
pre-hybridization, hybridization and slides washing are
imperative in enhancing foreground signal to background
noise ratios. Linear spectrum of signal intensity that corre-
lates with gene copy numbers without having to compen-
sate detection sensitivity is one of the key factors for high
quality cDNA analysis. Therefore, target labeling is a criti-
cal step to achieve consistently high signal images.
Typically, fluorescently-labeled cDNA is generated by
incorporation of conjugated nucleotide analogs during
the reverse transcription process. Depending upon the
detection system, labeled markers can be either radioac-
tive, color matrix or florescent. Florescence labeling out-
performs the other labeling methods because of the
versatile excitation and emission wave length. In addition,
it has the advantage of not being hazardous. Among the
fluorochrome, Cy3 (N, N8-(dipropyl)-tetramethylindo-
carbocyanine) and Cy5 (N, N8-(dipropyl)-tetramethylin-
dodicarbocyanine) are most commonly used in cDNA
microarray applications due to their distinct emission
(510 and 664 respectively). Cy5 labeled dUTP and dCTP
are less efficient in incorporation during the labeling reac-
tion compared to Cy3 labeled dUTP or dCTP and they are
more sensitive to photo bleach because of their chemical
structure. Therefore, labeling bias needs to be accurately
analyzed and results should be normalized according to
standard normalization procedures.
Target labeling can be divided into two major categories:
direct fluorescence incorporation and indirect fluores-
cence incorporation. The first category utilizes fluores-
cence-labeled dUTP or dCTP to partially substitute
unlabeled dTTP or dCTP in the RT reaction to generate
Cydye-labeled cDNA. This label incorporation method is
suitable for cDNA clone microarray using amplified aRNA
as templates or oligo array using amplified sRNA as tem-
plate.
A limitation of direct labeling consists in the fact that flu-
orescent nucleotides are not the normal substrates for
polymerases and some may be particularly sensitive to the
structural diversity of these artificial oligonucleotides. The
fluorescent moieties associated with these nucleotides are
often quite bulky and, therefore, the efficiency of incorpo-
ration of such nucleotides by polymerase tends to be
much lower than that of natural substrates. An alternative
is to incorporate, either by synthesis or by enzymatic activ-
ity, a nucleotide analog similar to the natural nucleotide
in structure featuring a chemically reactive group, such as
5-(3-Aminoallyl)-2'-deoxyuridine 5'-triphosphate (aa-
dUTP), to which a fluorescent dye, such as Cydye, may
then be attached [72]. The reactive amine of the aa-dUTP
can be incorporated by a variety of RNA-dependent and
DNA-dependent DNA polymerases. After removing free
nucleotides, the aminoallyl labeled samples can coupled
to dye, purified again, and then applied to a microarray
[73]. The optimized ratio of aa-dUTP versus dTTP in the
labeling reaction should be 2 to 3 respectively.
In theory, indirect outperforms direct labeling by reducing
of the cost and maximizing signal intensity through
increases in incorporation of fluorochrome or through
signal amplification using fluorescence-labeled antibody
or biotin-streptavdin complexes. However, more steps are
involved in the purification of the labeled target prior to
hybridization which make this strategies less frequently
used.
RNA amplification protocols
The protocols presented here are routinely used in our
laboratory in response to several inquires by interested
investigators, The protocol is based on a combination of
strategies discussed in the previous section that have been
used for RNA amplification that we have applied to opti-
mize TS-IVT following the original Eberwine's RNA ampli-
fication protocols.
Material and reagents
Dilute stock solution to the appropriate working concen-
tration.
dNTP mix solution (dATP, dCTP, dGTP, dTTP, 10 mM
each) (Pharmacia Cat# 27-2035-02)
Low T dNTP (5 mM dA, dG and dCTP, 2 mM dTTP)
RNasin Plus (20 units/µl) (Promega Cat# N2611)
Advantage PCR buffer (come with Advantage cDNA
polymerase)
Linear Acrylamide (0.1 ug/µl. Ambion; Cat# 9520)
Phenol: Chloroform: Isoamyl alcohol (25:24:1) (Boe-
hringer Mannhem Cat #101001)Page 6 of 11
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188233)
7.5 M ammonium acetate (Sigma; Cat# A2706)
DEPC treated H2O
In Vitro Tanscription Kit (Ambion; T7 Megascript Kit
#1334)
Cy-dUTP (1 mM Cy3 or Cy5)
1 M NaOH
500 mM EDTA
1 × TE
1 M Tris pH 7.5
50× Denhardt's blocking solution (Sigma; Cat# 2532)
Poly dA40–60 (8 mg/ml) (Pharmacia; Cat# 27-7988-01)
Human Cot I DNA (10 mg/ml) (Invitrogen; Cat# 15279-
011)
20 × SSC
10% SDS
T4gp32 protein (8 mg/ul) (USB Cat# 74029Y)
Enzymes
RNase H- MMLV Reverse Transcriptase (Superscript II)
(200 units/µl) (Invitrogen; Cat# 18064-071)
50× Advantage cDNA Polymerase mix (Clontech Cat#
8417-1)
RNase H (2 U/µl. Invitrogen; Cat# 18021-071)
10× T7 RNA polymerase mix (within the Megascript kit)
Primers
Oligo dT-T7 primer (5' AAA CGA CGG CCA GTG AAT
TGT AAT ACG ACT CAC TAT AGG CGC T(15) 3') (0.125–
0.25 µg/µl for the first round amplification depending on
the amount of input total RNA and 0.5 µg/µl for the sec-
ond round amplification) in RNase free water. Synthe-
sized primer should be SDS-PAGE purified to insure the
full length. The concentration of primer is varied accord-
ing to the starting material used. This promoter sequence
is much longer than the consensus sequence defined by
Dunn and Studier (1983) and can be purchased from
New England Biolabs and Stratagene Inc. In the extended
sequence shown here, the consensus sequence is embed-
ded in the between a 5'flanking region that provides space
for the T7 RNA polymerase to bind and a 3'-flanking tri-
nucleotide that stimulates transcription catalyzed by the
enzyme.
TS primer (5' AAG CAG TGG TAA CAA CGC AGA GTA
CGC GGG 3') (0.25 µg/µl) SDS-PAGE purified. According
to the Chenchik's [74] data, ribouncleotide GGG at the 3'
end should give the best TS effect instead of deoxinucle-
otide GGG. We have used TS primer with dGGG at the 3'
end in multiple experiments and achieved satisfying
results. The amount of TS primer used in the second
strand synthesis can be varied according to the amount of
starting material. We generally use 0.25 µg/µl when 3–6
ug of total RNA used and 0.125 µg/µl when less total RNA
used.
Random hexamer (dN6) (8 µg/µl).
Columns
Micro Bio-Spin Chromatograph column (Bio-gel P-6)
(Bio-Rad; Cat# 732–6222)
Microcon YM-30 column (Millipore; Cat# 42410).
Procedures
First strand cDNA synthesis
1. In PCR reaction tube, mix 0.01–5 µg total RNA in 9 µl
DEPC H2O with 1 µl (0.1–0.25 µg/µl) oligo dT(15)-T7
primer (5' AAA CGA CGG CCA GTG AAT TGT AAT ACG
ACT CAC TAT AGG CGC T(15) 3'), 1 ul of RNasin Plus and
heat to 70°C for 3 min. Cool to room temperature then
add the following reagents: (a master mix can be prepared
for multiple samples)
2. 4 µl 5 × First strand buffer
3. 1 µl (0.1–0.25 µg/µl) TS (template switch) oligo primer
4. 2 µl 0.1 M DTT
5. 2 µl 10 mM dNTP
6. 1 µl Superscript II
7. 0.5 µl of T4 gp32 (8 µg/µl)
50°C for 90 min in thermal cycler.
Second strand cDNA synthesis
1. Add 106 µl of DEPC treated H2O to the cDNA reaction
tubePage 7 of 11
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3. 3 µl 10 mM dNTP mix
4. 1 µl of RNase H
5. 3 µl Advantage cDNA Polymerase mix
Cycle at 37°C for 5 min to digest mRNA, 94°C for 2 min
to denature, 65°C for 1 min. for specific priming and
75°C for 30 min for extension.
Note: Since the TS primer which initiates the second
strand cDNA synthesis is already present in the first
strand cDNA synthesis reaction and has been primed to
the extended part of the cDNA, no additional primer is
required in this step.
Stop reaction with 7.5 µl 1 M NaOH solution containing
2 mM EDTA and incubate at 65°C for 10 min. to inacti-
vate enzymes.
(Reaction can be stopped after this step and the reaction
tube can be stored at -20°C.)
Double stranded cDNA cleanup
(This step is designed to prevent carry over of non-incor-
porated dNTP, primers and inactivated enzymes into the
following in vitro transcription. Keep in mind that
although the double stranded cDNAs are stable and will
not be affected by RNase contamination, they will be used
as template in the IVT reaction which is RNase free.)
Phenol-Chloroform-Isoamyl isolation and ethanol precipitation
Add 1 µl Linear Acrylamide (0.1 µg/µl) as DNA carrier to
the sample to enhance double stranded-cDNA precipita-
tion. Add 150 µl Phenol: Chloroform: Isoamyl alcohol
(25:24:1) to the double stranded cDNA tube and mix well
by pipetting (be careful not to spill or contaminate).
Transfer the slurry solution to Phase lock gel tube and spin
at 14,000 rpm for 5 min at room temperature. Transfer the
aqueous phase to RNase/DNase-free 1.7 ml tube and add
70 µl of 7.5 M ammonium acetate first and then 1 ml
100% ethanol (EtOH). Mix well. Centrifuge right away at
14,000 rpm for 20 min at room temperature to prevent
co-precipitation of oligos. (A visible small white pellet
should be seen at the bottom of the tube even if nano
grams of starting material have been used. This pellet sug-
gests successful precipitation.) Wash pellet with 800 µl
100% EtOH and spin down at maximum speed for 8 min.
Repeat this washing step one more time. Air dry or speed-
vac and re-suspend double stranded cDNA in 8 ul DEPC
H2O.
In Vitro Tanscription (Ambion; T7 Megascript Kit #1334)
2 µl of each 75 mM NTP (A, G, C and UTP)
2 µl reaction buffer
2 µl enzyme mix (RNase inhibitor and T7 phage RNA
polymerase)
8 µl double stranded cDNA
37°C for 5 hr.
According to Ambion, the incubation can be interrupted
by storing reaction tube at -20°C and resuming the incu-
bation later without losing efficiency.
Purification of amplified RNA
Any manufactured RNA isolation kit can be applied
Monophasic reagent such as TRIzol reagent from Gibco-
BRL, (Cat#15596) are used here based on the efficient
recovery of aRNA (RNeasy mini kit could be used for
aRNA purification instead of TRIzol but, in our experi-
ence, RNA recovering is about 50% of that recovered with
the TRIzol method.).
a. Add 0.5 ml of TRIzol solution to the transcription reac-
tion. Mix the reagents well by pipetting or gentle vortex-
ing.
b. Add 100 µl chloroform. Mix the reagents by inverting
the tube for 15 seconds. Allow the tube to stand at room
temperature for 2 – 3 minutes.
c. Centrifuge the tube at 10,000 g for 15 min at 4°C.
d. Transfer the aqueous phase to a fresh tube and add 250
µl of isopropanol.
e. Store the sample on ice for 5 minutes and then centri-
fuge at 10,000 g for 15 minutes.
f. Wash the pellet twice with 800 µl 70% EtOH
g. Allow the pellet to dry in air on ice and then dissolve it
in 20 µl DEPC H2O
h. Measure the quantity of RNA concentration spectro-
photometrically.
Second round of amplification
Mix amplified aRNA (0.5–1 µg) in 9 ul DEPC H2O with 1
µl (2 µg/µl) random hexamer (i.e. dN6) and heat to 70°C
for 3 min, cool to room temperature. Then add the follow-
ing reagents:Page 8 of 11
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2. 1 µl (0.5–1 µg/ul) oligo dT-T7 primer
3. 2 µl 0.1 M DTT
4. 1 µl RNAsin
5. 2 µl 10 mM dNTP
6. 1 µl Superscript II
42°C for 90 min.
(Note: More than 1 ug of aRNA is not suggested. Too
much template in IVT reaction could cause the amplifica-
tion to reach a plateau with loss of amplification linearity.
Because of random primer used here, 42°C in stead of
50°C is used)
From here, follow the previously described procedure
for second strand cDNA synthesis, double stranded
cDNA cleanup. In the second IVT, 40 ul of IVT reaction
mixture are suggested to use instead of 20 ul. RNA iso-
lation is followed.
Target labeling by reverse transcription
4 µl First strand buffer
1 µl dN6 primer (8 µg/µl)
2 µl 10× low T – dNTP (5 mM A, C and GTP, 2 mM dTTP)
2 µl Cy-dUTP (1 mM Cy3 or Cy5)
2 µl 0.1 M DTT
1 µl RNasin
3–6 µg amplified aRNA in 8 µl DEPC H2O
Mix well and heat to 65°C for 5 min then cool down to
42°C.
Add 1.5 µl SSII. Incubate for 90 min at 42°C. Add 2.5 µl
0.5 M EDTA and heat to 65°C for 1 min. Add 5 µl 1 M
NaOH and incubate at 65°C for 15 min to hydrolyze
RNA. Add 12.5 µl 1 M Tris immediately to neutralize the
pH. Bring volume to 70 µl by adding 35 µl of 1 × TE.
Note: The amounts of aRNA used for labeling depends on
the size of the array. If the array with 2000–8000 genes, 3
ug aRNA will be sufficient while a larger chip such as 16–
20 k will need 6 ug of aRNA. The labeling reaction com-
ponents do not need to be changed.
Target clean up
Prepare Bio-6 column and run target solution through it.
Collect flow through and add 250 µl 1 × TE to it. Concen-
trate target to ~20 µl using Microcon YM-30 column.
Hybridization
Combine Cy3 labeled reference sample and Cy5 labeled
target sample (adjust the color to purple) and then com-
plete dry the sample using speedvac. Resuspend sample in
37 µl volume (for 22 mm × 40 mm printing surface) con-
taining 1 µl 50× Denhardt's blocking solution, 1 µl poly
dA (8 µg/µl), 1 µl yeast tRNA (4 mg/ml), 10 µl Human
Cot I DNA, 3 µl 20× SSC, 1 µl of 10% SDS and 20 µl of
DEPC treated water. Heat sample for 2 min at 99°C and
apply target mixture to array slide, add coverslip, place in
humidified hyb chamber, and hybridize at 65°C over
night.
Washing
1. Wash with 2 × SSC + 0.1% SDS to get rid of the cover
slide.
2. Wash with 1 × SSC for 1 min.
3. Wash with 0.2 × SSC for 1 min.
4. Wash with 0.05 × SSC for 10 second
5. Centrifuge slide at 80–100 g for 3 min. (Slide can be put
in slide rack on microplate carriers or in 50 ml conical
tube and centrifuged in swinging-bucket rotor.)
Scan Slide
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